• Hemogenyx – positive developments on a number of fronts highlight undervaluation

    January 8, 2019 | Posted by

    By Richard Gill, CFA Shares in Hemogenyx (HEMO) put in a decent rise yesterday after the preclinical-stage biopharmaceutical company announced a lengthy and positive update on developments across its portfolio. Hemogenyx is focused on the discovery, development and commercialisation of novel therapies and treatments relating to bone marrow/hematopoietic (blood-forming) stem cell (BM/HSC) transplants for blood […]